Sakai et al., 1980 - Google Patents

Association of gross virus-associated cell-surface antigen with liposomes

Sakai et al., 1980

View PDF
Document ID
15633332883192225054
Author
Sakai F
Gerlier D
Doré J
Publication year
Publication venue
British Journal of Cancer

External Links

Snippet

Abstract Gross Cell-Surface Antigen (GCSAa) was obtained from W/Fu (C58NT) D lymphoma cells by Nonidet P40 (NP40) or 3M KCl extraction and further purified by Sephadex G200 filtration. GCSAa was associated with lipids (dipalmitoylphosphatidycholine …
Continue reading at www.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension

Similar Documents

Publication Publication Date Title
US4900549A (en) Process for preparing immunogenic complexes and pharmaceutical composition containing these complexes
KR940001373B1 (en) Process for preparing influenza vaccine
US5928647A (en) Inducing cytotoxic T lymphocyte responses
Garcon et al. Universal vaccine carrier. Liposomes that provide T-dependent help to weak antigens.
JPH0751514B2 (en) Method for producing immunogenic complex
Shek et al. Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation.
EP0542923B1 (en) Liposomes that provide thymic dependent help to weak vaccine antigens
Chander et al. Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160
Sakai et al. Association of gross virus-associated cell-surface antigen with liposomes
Kersten et al. Immunogenicity of liposomes and iscoms containing the major outer membrane protein of Neisseria gonorrhoeae: influence of protein content and liposomal bilayer composition
LeGrue Carrier and adjuvant properties of liposome-borne tumor-specific antigens
Kramp et al. Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines
McWilliam et al. Production of multilamellar, small unilamellar and reverse-phase liposomes containing house dust mite allergens: potential adjuvants in the immunotherapy of allergic disease
Bakouche et al. Presentation of an MuLV-related tumour antigen in liposomes as a potent tertiary immunogen after adoptive transfer.
Kossovsky et al. Preservation of surface‐dependent properties of viral antigens following immobilization on particulate ceramic delivery vehicles
Diminsky et al. Structural and functional characterization of liposomal recombinant hepatitis B vaccine
Thérien et al. Immunopotentiation of the humoral response by liposomes: effect of a T cell polyclonal activator
Geiger et al. The use of antibody-coated liposomes as a target cell model for antibody-dependent cell-mediated cytotoxicity.
Bergers et al. Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells
Bergers et al. Liposomes as vehicles for the presentation of tumor-associated antigens to the immune system
AU616040B2 (en) Agents for inhibiting adsorption of proteins on the liposome surface
Tan The applications of liposomes in immunoprophylaxis and immunotherapy
Mannino et al. Liposomes as adjuvants for peptides: Preparation and use of immunogenic peptide-phospholipid complexes
Eriksson The use of fluorescent lipid as a non-covalent bound tracer of integral membrane proteins
Gerlier et al. Adjuvant Effect of Liposome Presentation of Soluble Tumour Associated Antigen